Article
Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven…
medRxiv · 2021 · Cottone, L.; Ligammari, L.; Knowles, H. J.; Lee, H.-M.; Henderson, S.; Bianco, S.; Davies, C.; Strauss, S.; Amary, F.; Leite, A. P.; Tirabosco, R.; Haendler, K.; Schultze, J. L.; Herrero, J.; ODonnell, P.; Grigoriadis, A. E.; Salomoni, P.; Flanagan, A. M.
Key facts
| Title | Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone. |
|---|---|
| First author | Cottone, L.; Ligammari, L.; Knowles, H. J.; Lee, H.-M.; Henderson, S.; Bianco, S.; Davies, C.; Strauss, S.; Amary, F.; Leite, A. P.; Tirabosco, R.; Haendler, K.; Schultze, J. L.; Herrero, J.; ODonnell, P.; Grigoriadis, A. E.; Salomoni, P.; Flanagan, A. M. |
| Journal | medRxiv |
| Published | Dec 29, 2021 |
| DOI | 10.1101/2021.12.27.474195 |
| Devices mentioned | BK110039, DEN000008, K022086, K103302, K202641, K231013, K800781 |
| Product codes mentioned | JCI, KIP, KIT, MVU, NDS, NJT, OOI, PFT, KIS, PCA, QBD |
At a glance
- 1–9 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1